Shares of Kura Oncology (KURA, Financial) jumped 12% following a mention on CNBC's "Mad Money" by Jim Cramer. The surge comes after the recent FDA approval of their cancer drug, Komzifti (ziftomenib), for treating acute myeloid leukemia. This approval also triggered a $135 million milestone payment from partner Kyowa Kirin. Cramer highlighted the speculative potential of owning stocks in effective cancer treatments.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.